A prospective randomized Phase III trial to evaluate optimal treatment duration of first-line bevacizumab in combination with carboplatin and paclitaxel in patients with primary epithelial ovarian, fallopian tube or peritoneal cancer. The BOOST (Bevacizumab Ovarian Optimal Standard Treatment) Trial
Following primary cytoreductive surgery, patients with newly diagnosed FIGO stage IIb - IV (all grades and all histological types) epithelial ovarian cancer (EOC), fallopian tube carcinoma (FTC) or primary peritoneal carcinomas (PPC) with indication for a platin/paclitaxel chemotherapy
